CTRI/2019/06/019749已完成2 期
An open labelled non- randomized phase II comparative clinical trial to evaluate the therapeutic efficacy of SIDDHAR YOGAM THERAPY and NAAVAL PAZHA KARPAM [ SIDDHA KALPA MEDICINE-INTERNAL] for NEERIZHIVU[DIABETES MELLITUS]
H JESIMA BARVEE0 个研究点目标入组 40 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •patients with the symptoms of diabetes mellitus not more than 2 years are included
- •patient willing to give blood and urine samples before and after treatment
- •patient with blood sugar level of about more than 126mg/dl less than 250 mg/dl Hba1c more than 6.5 and less than 10
- •willing to participate in study and signing consent by fulfiling the condition of proforma are included
排除标准
- •Age group less than 35
- •chronic diabeic cases for duration more than 2 years
- •Ischaemic heart disease
- •Diabetic foot and ulcer
- •Gestational diabetes mellitus/other specific types
- •Lactating mother
- •Chronic liver disease
- •chronic renal disease
研究者
相似试验
已完成
2 期
Clinical trial on effectiveness of SIDDHAR YOGAM THERAPY and Siddha Kalpa Medicine Vilampazha karpam [Internal] in the management of â??Vatha Pitham [Systemic Hypertension]CTRI/2019/06/019956Joshi40
已完成
2 期
Clinical trial on trial on eraippu erumal with yoga therapyCTRI/2019/06/019754S MUTHU VIGNESH40
已完成
2 期
TO EVALUATE THE THERAPEUTIC EFFICACY OF â??POTTANAMâ?? AS EXTERNAL THERAPY and SIDDHA POLYHERBAL FORMULATION â??AAYIL PATTAI CHOORANAMâ?? (INTERNAL) IN THE TREATMENT OF â??CEGANA VATHAMâ?? (CERVICAL SPONDYLOSIS)CTRI/2019/06/019936BKaruppannan40
进行中（未招募）
1 期
A phase 2 study evaluating S 95005 plus bevacizumab and capecitabine plus bevacizumab in patients with previously untreated colorectal cancer who are non-eligible for intensive therapyMetastatic colorectal cancerMedDRA version: 21.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-004544-18-GBInstitut de Recherches Internationales Servier153
进行中（未招募）
1 期
A phase 2 study evaluating S 95005 plus bevacizumab and capecitabine plus bevacizumab in patients with previously untreated colorectal cancer who are non-eligible for intensive therapyMetastatic colorectal cancerMedDRA version: 19.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-004544-18-NLInstitut de Recherches Internationales Servier150